News
Public · Published
STRATEC SE (SBS) Sells Diatron For €10M, Books €44.1M Impairment, Lifts 2026 Margin Outlook
STRATEC SE agreed to sell Diatron MI for €10M, with potential earn-outs, or additional payments tied to future results. It will record €44.1M in non-cash impairments and a €4–9M negative deconsolidation effect, while guiding to a 2026 adjusted EBIT margin of 13–15% on stable to slightly higher sales.
Published:
Updated:
What happened
STRATEC SE agreed to sell Diatron MI for €10M, with potential earn-outs, or additional payments tied to future results. It will record €44.1M in non-cash impairments and a €4–9M negative deconsolidation effect, while guiding to a 2026 adjusted EBIT margin of 13–15% on stable to slightly higher sales.
Confirmed
Global impact / market context
The sale removes a unit described as loss-making, which could improve the profitability of the remaining business. However, the impairments and deconsolidation effect will weigh on reported earnings even though they are described as non-cash, while the higher margin outlook depends on execution.
Analyst inference
The outlook points to stronger profit per sale rather than rapid growth: 2026 sales are expected to be stable to slightly higher, alongside a 13–15% adjusted EBIT margin. Investors will need to distinguish these adjusted targets from reported results, which face one-time charges.
Analyst inference
What to watch
- Watch whether the Diatron MI sale closes on schedule and whether any earn-outs become payable; completion determines when the unit leaves STRATEC’s accounts. Analyst inference
- Track the €44.1M impairment and €4–9M deconsolidation effect in reported results; these are expected accounting charges, not cash payments, according to the article. Confirmed
- Compare 2026 sales and adjusted EBIT margin with the guidance of stable to slightly higher sales and 13–15%; delivery would test the margin-focused plan. Analyst inference